The pharmacogenetics of analgesia: Toward a genetically-based approach to pain management

Pharmacogenomics

Volumn 2, Issue 3, 2001, Pages 177-194

  Flores, C M ^a   Mogil, J S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Allelic polymorphism; Analgesia; Antinociception; Cytochrome P450 (CYP2D6); Nicotinic; Opioid; Pain; Pharmacogenetic variability; Quantitative trait locus (QTL); Sex

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ALPRAZOLAM; ANALGESIC AGENT; CARBACHOL; CLONIDINE; COCAINE; CODEINE; CYTISINE; DIAMORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; EPIBATIDINE; KETANSERIN; LEVORPHANOL; MORPHINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NALOXONE; NEOSTIGMINE; NICOTINE; NITROUS OXIDE; NOCICEPTIN; OPIATE; OXYCODONE; OXYMORPHONE; PHENTOLAMINE; PILOCARPINE; PROTIRELIN; SEROTONIN; UNINDEXED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; GENDER; GENETIC VARIABILITY; HUMAN; MALE; MOUSE; NONHUMAN; PAIN; PAIN THRESHOLD; PHARMACODYNAMICS; PHARMACOGENETICS; RACE DIFFERENCE; RAT; REVIEW;

ANALGESICS; ANIMALS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; PAIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; QUANTITATIVE TRAIT, HERITABLE; SEX FACTORS;

EID: 0034853632     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.2.3.177     Document Type: Review

References (110)

1. The optimal dose of morphine
2. Response of experimental pain to analgesic drugs I. Morphine, aspirin and placebo
3. Appraisal of codeine as an analgesic in older patients
4. Analgesic responses to morphine and placebo in individuals with postoperative pain
5. An appraisal of codeine as an analgesic: Single dose analysis
6. Profiles of opioid analgesia in humans on experimental pain
7. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions
8. Individual variability in the response to different opioids: Report of five cases
9. Efficacy of controlled-release codeine in chronic non-malignant pain: A randomized, placebo controlled clinical trial
10. The influence of cultural group on the undertreatment of postoperative pain
11. Gender and ethnic stereotyping and narcotic analgesic administration
12. Opioid requirements and responses in Asians
13. The genetics of pain and pain inhibition
14. The genetic mediation of individual differences in sensitivity to pain and its inhibition
15. Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception
16. Gender differences in opioid-mediated analgesia: Animal and human studies
17. Sex differences in supraspinal morphine analgesia are dependent on genotype
18. Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype
19. Herion acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception
20. Analgesic response in offspring of crosses between herion Delta (Swiss Webster) and mu (ICR) responding mice
21. Sexually dimorphic linkage of a gene on distal chromosome 8 to kappa-opioid analgesia
22. Sex differences in opioid analgesia: Of mice and women
23. The function of noradrenergic neurons in mediating antinociception induced by electrical stimulation of the locus coeruleus in two different sources of Sprague-Dawley rats
24. Heritability of nociception. I. Responses of eleven inbred mouse strains on twelve measures of nociception
25. Heritability of nociception. II. 'Types' of nociception revealed by genetic correlation analysis
26. Genetic influences in opioid analgesic sensitivity in mice
27. Contributo sperimentale all'ipotesi della smetilazione della codeine nell' organismo. I. Influence della dose sull'assuefazione alla codeine. II. Assuefazione alla codeine attenuata con somministrazione prolungata di morfina
28. Polymorphic hydroxylation of debrisoquine in man
29. N-oxidation of sparteine in man: A new pharmacogenetic defect
30. 3H]GBR-12935 binding proteins
31. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activation by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6
32. The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects
33. The molecular basis of genetic polymorphisms of drug metabolism
34. Absence of hepatic cytochrome P450buf1 causes genetically deficient debrisoquine oxidation in man
35. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
36. Evolution of a highly polymorphic human cytochrome P450 gene: CYP2D6
37. Polymorphic O-demethylation of codeine
38. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450dbl/bufl)
39. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation
40. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten Extensive metabolisers and one poor metaboliser of dextromethorphan
41. Impact of environmental and genetic factors on codeine analgesia
42. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine
43. Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects
44. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation
45. The influence of pharmacogenetics on opioid analgesia: Studies with codeine and oxycodone in the Sprague-Dawley Dark Agouti rat model
46. B agonist baclofen
47. Gender difference in analgesic response to the kappa-opioid pentazocine
48. Kappa-opioids produce significantly greater analgesia in women than in men
49. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain
50. Pain inhibition, nicotine and gender
51. The promise and pitfalls of a nicotinic cholinergic approach to pain management
52. Finding pain genes: Bottom-up and top-down approaches
53. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
54. Differentiation of neurochemical basis of stress-induced analgesia in mice by selective breeding
55. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: Influence of nociceptive assay
56. Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical Tests
57. Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450-3A4
58. Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil
59. The average dose-plasma concentration relationship and interindividual variability in patients
60. Chromosome mapping of gene loci affecting morphine and amphetamine responses in BXD recombinant inbred mice
61. Localization to chromosome 10 of a locus influencing morphine analgesia in crosses derived from C57BL/6 and DBA/2 strains
62. J (Beige) mice: Differential sensitivity in the tail-flick test to centrally administered mu- and delta-opioid receptor agonists
63. Microinjection of morphine into the rostral ventromedial medulla produces greater antinociception in male compared to female rats
64. The μ opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception and opiate responses
65. Incomplete cross tolerance and multiple mu opioid peptide receptors
66. Differences in morphine reinforcement property in two inbred rat strains: Associations with cortical receptors, behavioral activity, analgesia and the cataleptic effects of morphine
67. Opiate receptors in mice: Genetic differences
68. Ethanol-induced changes of dopaminergic function in three strains of mice characterized by a different population of opiate receptors
69. Strain difference in the effects of morphine on the rectal temperature and respiratory rate in male mice
70. Opioids and behavior: Genetic aspects
71. A genetic analysis of morphine-induced running and analgesia in the mouse
72. Analgesia and motor activity elicited by morphine and enkephalins in two inbred strains of mice
73. Quantitative trait loci influencing morphine antinociception in four mapping populations
74. Pharmacogenetic evidence for the involvement of 5-hydroxytryptamine (serotonin)-1B receptors in the mediation of morphine antinociceptive sensitivity
75. Strain differences in mice antinociception: Relationship between alprazolam and opioid receptor subtypes
76. Endorphinergic mechanism in the central cardiovascular and analgesic effects of clonidine 1
77. The genetic characteristics of the brain alpha 2-adrenergic and S2-serotoninergic systems in the realization of the tail-jerk pain reflex and its morphine suppression in rats
78. Inherited, selective hypoanalgesic response to cytisine in the tail-flick test in CF-1 mice
79. Analgesic effects of D-amino acids in four inbred strains of mice
80. Selective breeding for high and low levels of opiate-induced analgesia in mice
81. The modulating effect of the thyrotropin-releasing hormone on genetically induced mechanisms of morphine sensitivity
82. Comparison of the effects of morphine on locomotor activity, analgesia and primary and protracted physical dependence in six mouse strains
83. Genetically determined differences in The effects of morphine on mice
84. Strain differences in the analgesic response to morphine as measured on the hot plate
85. Morphine analgesia, tolerance and dependence in mice from different strains and vendors
86. Genetic differences in morphine sensitivity, tolerance and withdrawal in rats
87. Morphine analgesia and tolerance in mice selectively bred for divergent swim stress-induced analgesia
88. Aggression modulates genetic influence on morphine analgesia as assessed using a classical Mendelian cross analysis
89. One or two genetic loci mediate high opiate analgesia in selectively bred mice
90. A pharmacogenetic approach to the mechanisms of action of opiates
91. 2O) antinociception
92. Influence of inheritance and fostering on sensitivity to effects of morphine on nociception and locomotor activity in two inbred rat strains
93. The effects of p-chlorophenylalanine on morphine analgesia, tolerance and dependence development in two strains of rats
94. Relationship between hypothalamic-pituitary-adrenal activity and blockade of tolerance to morphine analgesia by pain: A strain comparison
95. Rat strain differences in the potentiation of morphine-induced analgesia by stress
96. Strain difference in reversal of conditional analgesia by opioid antagonists
97. Systemic administration of naloxone produces analgesia in BALB/c mice in the formalin pain test
98. The genetic characteristics of the analgesic action of substance P, bradykinin and thyroliberin in the rats of 2 inbred strains
99. Strain-dependent effects of supraspinal orphanin FQ/nociceptin on thermal nociceptive sensitivity in mice
100. Strain differences in adrenergic sensitivity of neuropathic pain behaviors in an experimental rat model
101. Age, strain and anesthetic dependent differences in the nociceptive responses produced by i.v. 5-HT in the rat
102. Sex differences in cholinergic analgesia II
103. Roles of gender and gonadectomy in pilocarpine and clonidine analgesia in rats
104. Sex differences in cocaine- and nicotine-induced antinociception in the rat
105. Influence of gender and sex hormones on nicotine acute pharmacological effects in mice
106. Sex differences in cholinergic analgesia I
107. Sex differences in morphine analgesia
108. The pattern of postoperative analgesic administration in non-English speaking Asian women following caesarean section
109. Inter-ethnic differences in postoperative pethidine requirements
110. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial